Entry Point Capital, LLC Roivant Sciences Ltd. Transaction History
Entry Point Capital, LLC
- $171 Million
- Q3 2024
A detailed history of Entry Point Capital, LLC transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Entry Point Capital, LLC holds 12,479 shares of ROIV stock, worth $139,140. This represents 0.08% of its overall portfolio holdings.
Number of Shares
12,479
Previous 1,148
987.02%
Holding current value
$139,140
Previous $12.1 Million
98.81%
% of portfolio
0.08%
Previous 0.02%
Shares
3 transactions
Others Institutions Holding ROIV
# of Institutions
315Shares Held
507MCall Options Held
1.26MPut Options Held
2.52M-
Sb Investment Advisers (Uk) LTD London, X065.9MShares$735 Million6.27% of portfolio
-
Qvt Financial LP New York, NY65.8MShares$734 Million73.2% of portfolio
-
Viking Global Investors LP54.1MShares$603 Million2.42% of portfolio
-
Vanguard Group Inc Valley Forge, PA41.7MShares$465 Million0.01% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$394 Million0.01% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $7.85B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...